1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 8
2.1 What Is This Report About? 8
2.2 Insulin Delivery Market Segmentation 8
2.3 Definitions of Markets Covered in the Report 9
3 Insulin Delivery Market, EU5 10
3.1 Insulin Delivery Market, EU5, Revenue ($m), 2015-2025 10
3.2 Insulin Delivery Market, EU5, Revenue ($m), 2015-2025 12
3.3 Insulin Delivery Market, EU5, Volume (Units), 2015-2025 14
3.4 Insulin Delivery Market, EU5, Volume (Units), 2015-2025 16
3.5 Insulin Delivery Market, EU5, Company Share by Revenue ($m), 2019 18
4 Insulin Delivery Market, France 20
4.1 Insulin Delivery Market, France, Revenue ($m), 2015-2025 20
4.1.1 Insulin Pens Market, France, Revenue ($m), by Segment, 2015-2025 22
4.1.2 Insulin Pumps Market, France, Revenue ($m), by Segment, 2015-2025 24
4.2 Insulin Delivery Market, France, Volume (Units), 2015-2025 26
4.2.1 Insulin Pens Market, France, Volume (Units), by Segment, 2015-2025 28
4.2.2 Insulin Pumps Market, France, Volume (Units), by Segment, 2015-2025 30
4.3 Insulin Delivery Market, France, Average Price ($), 2015-2025 32
4.4 Insulin Delivery Market, France, Distribution Share by Revenue ($m), 2019 33
4.5 Insulin Delivery Market, France, Company Share by Revenue ($m), 2019 34
5 Insulin Delivery Market, Germany 36
5.1 Insulin Delivery Market, Germany, Revenue ($m), 2015-2025 36
5.1.1 Insulin Pens Market, Germany, Revenue ($m), by Segment, 2015-2025 38
5.1.2 Insulin Pumps Market, Germany, Revenue ($m), by Segment, 2015-2025 40
5.2 Insulin Delivery Market, Germany, Volume (Units), 2015-2025 42
5.2.1 Insulin Pens Market, Germany, Volume (Units), by Segment, 2015-2025 44
5.2.2 Insulin Pumps Market, Germany, Volume (Units), by Segment, 2015-2025 46
5.3 Insulin Delivery Market, Germany, Average Price ($), 2015-2025 48
5.4 Insulin Delivery Market, Germany, Distribution Share by Revenue ($m), 2019 49
5.5 Insulin Delivery Market, Germany, Company Share by Revenue ($m), 2019 50
6 Insulin Delivery Market, Italy 52
6.1 Insulin Delivery Market, Italy, Revenue ($m), 2015-2025 52
6.1.1 Insulin Pens Market, Italy, Revenue ($m), by Segment, 2015-2025 54
6.1.2 Insulin Pumps Market, Italy, Revenue ($m), by Segment, 2015-2025 56
6.2 Insulin Delivery Market, Italy, Volume (Units), 2015-2025 58
6.2.1 Insulin Pens Market, Italy, Volume (Units), by Segment, 2015-2025 60
6.2.2 Insulin Pumps Market, Italy, Volume (Units), by Segment, 2015-2025 62
6.3 Insulin Delivery Market, Italy, Average Price ($), 2015-2025 64
6.4 Insulin Delivery Market, Italy, Distribution Share by Revenue ($m), 2019 65
6.5 Insulin Delivery Market, Italy, Company Share by Revenue ($m), 2019 66
7 Insulin Delivery Market, Spain 68
7.1 Insulin Delivery Market, Spain, Revenue ($m), 2015-2025 68
7.1.1 Insulin Pens Market, Spain, Revenue ($m), by Segment, 2015-2025 70
7.1.2 Insulin Pumps Market, Spain, Revenue ($m), by Segment, 2015-2025 72
7.2 Insulin Delivery Market, Spain, Volume (Units), 2015-2025 74
7.2.1 Insulin Pens Market, Spain, Volume (Units), by Segment, 2015-2025 76
7.2.2 Insulin Pumps Market, Spain, Volume (Units), by Segment, 2015-2025 78
7.3 Insulin Delivery Market, Spain, Average Price ($), 2015-2025 80
7.4 Insulin Delivery Market, Spain, Distribution Share by Revenue ($m), 2019 81
7.5 Insulin Delivery Market, Spain, Company Share by Revenue ($m), 2019 82
8 Insulin Delivery Market, United Kingdom 84
8.1 Insulin Delivery Market, United Kingdom, Revenue ($m), 2015-2025 84
8.1.1 Insulin Pens Market, United Kingdom, Revenue ($m), by Segment, 2015-2025 86
8.1.2 Insulin Pumps Market, United Kingdom, Revenue ($m), by Segment, 2015-2025 88
8.2 Insulin Delivery Market, United Kingdom, Volume (Units), 2015-2025 90
8.2.1 Insulin Pens Market, United Kingdom, Volume (Units), by Segment, 2015-2025 92
8.2.2 Insulin Pumps Market, United Kingdom, Volume (Units), by Segment, 2015-2025 94
8.3 Insulin Delivery Market, United Kingdom, Average Price ($), 2015-2025 96
8.4 Insulin Delivery Market, United Kingdom, Distribution Share by Revenue ($m), 2019 97
8.5 Insulin Delivery Market, United Kingdom, Company Share by Revenue ($m), 2019 98
9 Overview of Key Companies in EU5 Insulin Delivery Market 100
9.1 Novo Nordisk AS 100
9.1.1 Company Overview 100
9.2 Sanofi 100
9.2.1 Company Overview 100
9.3 Eli Lilly and Co 100
9.3.1 Company Overview 100
9.4 Medtronic Plc 101
9.4.1 Company Overview 101
9.5 Ypsomed Holding AG 101
9.5.1 Company Overview 101
9.6 F. Hoffmann-La Roche Ltd 101
9.6.1 Company Overview 101
10 Insulin Delivery Market Pipeline Products 102
11 Recent Developments 104
11.1 Corporate Communications 104
11.1.1 Feb 27, 2020: ConvaTec Group: Non-executive director appointment 104
11.1.2 Feb 24, 2020: 2020 Catalyst award winner Medtronic hires Chief Inclusion and Diversity Officer 104
11.1.3 Feb 24, 2020: 2020 Catalyst Award Winner Medtronic hires Chief Inclusion and Diversity Officer 105
11.1.4 Feb 22, 2020: Bayer Cares Foundation donates over EUR 363,000 to support 94 social projects in 32 countries worldwide 105
11.1.5 Nov 14, 2019: Medtronic highlights leadership in inclusion, diversity, and equity in 2019 integrated performance report 105
11.1.6 Oct 21, 2019: Sean Salmon named executive vice president and group president of Medtronic Diabetes 106
11.1.7 Sep 30, 2019: Johnson & Johnson appoints Carlton Lawson to area Managing Director, Consumer, Northern Europe 107
11.1.8 Sep 10, 2019: Bayer reduces size of board of management from seven to five members 108
11.1.9 Sep 09, 2019: Midatech Pharma announces directorate change 109
11.1.10 Sep 03, 2019: Bayer appoints Marianne De Backer Head of Pharmaceuticals Business Development & Licensing and Member of Executive Committee 109
11.1.11 Aug 28, 2019: Medtronic announces planned leadership succession 110
11.1.12 Aug 19, 2019: John McAdam appointed Chairman of ConvaTec 112
11.1.13 Jul 31, 2019: Midatech Pharma: Appointment of Non-Executive Director 112
11.1.14 Jul 24, 2019: Former Medtronic Executive Sean Ginney named VP of Sales at Current Health 113
11.1.15 Jun 25, 2019: ConvaTec Group: Board Change 114
11.1.16 Jun 07, 2019: Jubilant DraxImage receives CE Mark certificate for its medical device RUBY Rubidium Elution System (RbES) and Proprietary RUBY 114
Consumable Accessories 114
11.1.17 Apr 16, 2019: Ginkgo Bioworks appoints former Bayer CEO Marijn Dekkers as Chairman of its Board of Directors 115
11.1.18 Apr 12, 2019: Dr. Monika Lessl to lead both the Bayer Science and the Bayer Cares Foundations 116
11.2 Financial Announcements 117
11.2.1 Feb 28, 2020: ConvaTec Group: Audited annual results for the twelve months ended 31 December 2019 117
11.2.2 Feb 18, 2020: Medtronic reports third quarter financial results 2020 118
11.2.3 Feb 05, 2020: Novo Nordisk's operating profit increased by 11% in Danish kroner and by 6% at constant exchange rates (CER) in 2019 120
11.2.4 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019 121
11.2.5 Nov 05, 2019: Ypsomed grows strongly in the pen business 123
11.2.6 Nov 01, 2019: Novo Nordisk's operating profit increased by 11% in Danish kroner and by 5% at constant exchange rates (CER) in the first nine months of 2019 125
11.2.7 Sep 30, 2019: Midatech Pharma: Interim results for the six months ended 30 June 2019 126
11.2.8 Aug 20, 2019: Medtronic reports first quarter financial results for 2019 131
11.2.9 Aug 08, 2019: Novo Nordisk's operating profit increased by 12% in Danish kroner and by 6% at constant exchange rates (CER) in the first six months of 2019 133
11.2.10 Aug 01, 2019: ConvaTec Group first half results 2019 134
11.2.11 Jul 30, 2019: Bayer on track in operational business 140
11.2.12 May 23, 2019: Medtronic announces fiscal year and fourth quarter 2019 financial results 143
11.2.13 May 20, 2019: Ayala Pharmaceuticals to present at ASCO Annual Meeting on investigational drug AL101 in adenoid cystic carcinoma and triple negative breast cancer 145
11.2.14 May 03, 2019: Novo Nordisk's operating profit increased by 14% in Danish kroner and by 8% at constant exchange rates (CER) in the first three months of 2019 147
11.2.15 Apr 24, 2019: Midatech Pharma: Audited financial results for the year ended 31 December 2018 148
11.3 Legal And Regulatory 149
11.3.1 Oct 03, 2019: Lilly announces voluntary delisting from Euronext Paris 149
11.3.2 Sep 30, 2019: Adocia announces receipt of USD
14.3 million payment from Eli Lilly following arbitration conclusion and the decision by mutual consent with Eli Lilly to conclude the civil case 150
11.3.3 Aug 23, 2019: Adocia announces that the American Arbitration Association Tribunal Dismissed all Claims in Second Phase of Arbitration With Eli Lilly 150
11.3.4 Aug 16, 2019: Novo Nordisk: Securities lawsuit filed in Denmark against Novo Nordisk 151
11.4 Other Significant Developments 151
11.4.1 Feb 27, 2020: Bayer reaches agreement with stockholder Prof. Strenger on voluntary special audit of due diligence procedures 151
11.4.2 Dec 10, 2019: Bayer to significantly step-up its sustainability efforts 152
11.4.3 Oct 21, 2019: CRISPR Therapeutics and Bayer announce an update on Casebia Therapeutics 154
11.4.4 Oct 10, 2019: clayton cuts ribbon on historic biopharma infrastructure 154
11.4.5 Sep 06, 2019: Novo Nordisk to provide discounted insulin products in US 155
11.4.6 Jun 19, 2019: Gamida Cell and Lonza establish commercial manufacturing agreement for omidubicel 156
11.4.7 May 23, 2019: Ypsomed increases EBIT and invests in long-term profitability 157
11.4.8 Apr 30, 2019: Novo Nordisk to achieve target of 100% renewable power in production and launches new ambition aiming for zero environmental impact 159
11.4.9 Apr 25, 2019: Bayer: strong operational start to the year 160
11.5 Strategy And Business Planning 162
11.5.1 Dec 04, 2019: Lumeon and Medtronic partner to deliver new models of care in Europe 162
11.5.2 Aug 30, 2019: Ypsomed expands headquarters in Burgdorf 163
11.5.3 Aug 22, 2019: Ypsomed opens production plant in Schwerin 163
12 Appendix 165
12.1 Research Methodology 166
12.1.1 Coverage 166
12.1.2 Secondary Research 166
12.1.3 Primary Research 167
12.1.4 Market Modeling and Forecasting 168
12.1.5 Company Share Analysis 169
12.1.6 Distribution Share Analysis 169
12.1.7 Benchmarking 170
12.2 GlobalData Consulting 170
12.3 Contact Us 171
12.4 Disclaimer 171